A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma

This study tests a new cell therapy called ESO-T01 for people with multiple myeloma — a cancer of the blood — that has come back or stopped responding to other treatments. ESO-T01 uses specially engineered immune cells designed to attack myeloma cells. **You may be eligible if...** - You are 18 or older with confirmed multiple myeloma - Your myeloma has returned or stopped responding after at least 2 prior treatment courses - Your cancer can be measured through blood or urine tests - Your overall health and organ function meet study requirements **You may NOT be eligible if...** - You have had a bone marrow transplant from a donor within the past 6 months, or your own stem cells transplanted in the past 3 months - You have another active cancer - You have serious heart, lung, or liver problems - You have active infections including HIV, hepatitis B, or hepatitis C Talk to your doctor to see if this trial is right for you.